Leerink Upgrades Relmada Therapeutics With $8 Price Target
Leerink starts coverage on Relmada Therapeutics, upgrades the stock to Outperform, and highlights strong potential for its bladder cancer program NDV-01.
/ 676 items
#Healthcare↓
Bausch Health’s Liver Drug Fails in Late-Stage Trials
Bausch Health said its experimental liver treatment did not meet goals in Phase 3 trials, sending shares lower in early trading.
Oppenheimer Starts Coverage on Coherus Oncology With Bullish Outlook
Oppenheimer initiates coverage of Coherus Oncology with an Outperform rating and a $10 price target, highlighting promising cancer drug programs and key clinical data expected in 2026.
Roth Capital Starts Coverage on Arcturus Therapeutics With Buy Rating
Roth Capital initiates coverage of Arcturus Therapeutics with a Buy rating and $20 price target, citing undervaluation and strong rare disease pipeline potential.
Inspire Medical Stock Falls After Medicare Reimbursement Correction
Inspire Medical shares dropped after Medicare corrected a reimbursement error, prompting Oppenheimer to downgrade the stock while Evercore remained optimistic.
Ascendis Pharma Stock Jumps on Takeover Rumors
Ascendis Pharma shares rose 5% after new takeover speculation involving European pharmaceutical companies, according to market chatter.